Results 131 to 140 of about 2,121,152 (251)

Expert consensus document on β-adrenergic receptor blockers

Кардиоваскулярная терапия и профилактика, 2005
The task Force on Beta-Blockers of the European Society of ...
article Editorial
doaj  

Subcellular β-Adrenergic Receptor Signaling in Cardiac Physiology and Disease. [PDF]

J Cardiovasc Pharmacol, 2022
Wei W, Smrcka AV.
europepmc   +1 more source

Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study

Alimentary Pharmacology &Therapeutics, EarlyView.
Summary of a multicentre TriNetX study evaluating outcomes after percutaneous coronary intervention (PCI) in patients with cirrhosis. Cirrhosis was associated with higher 1‐year gastrointestinal bleeding and mortality, especially with decompensated disease.
Dhir Gala, Sameer Rao, Manas Gunani, Kajol Shah, Anand V. Kulkarni, Karn Wijarnpreecha, Daniel Q. Huang, Pojsakorn Danpanichkul, Ahmed Al‐Khazraji, Kaveh Hajifathalian, Vivek Lingiah, Paul Gaglio, Nikki Duong, Christine Gerula   +13 more
wiley   +1 more source

CD44 regulates Epac1-mediated β-adrenergic-receptor-induced Ca²⁺-handling abnormalities: implication in cardiac arrhythmias. [PDF]

J Biomed Sci, 2023
Chan YH, Tsai FC, Chang GJ, Lai YJ, Chang SH, Chen WJ, Yeh YH.   +6 more
europepmc   +1 more source

PDE4D and PDE3B orchestrate distinct cAMP microdomains in 3T3‐L1 adipocytes

British Journal of Pharmacology, EarlyView.
Basal conditions: •Ins/PDE3B lowers cytoplasmic cAMP (cyt‐cAMP) without affecting plasma membrane cAMP (pm‐cAMP). •Insulin decreases lipid droplet cAMP (LD‐cAMP) independent of PDE3B. •FGF1/PDE4D modestly reduces both cyt‐ and pm‐cAMP, while PDE4D alone can modulate LD‐cAMP. ISO stimulation: •Ins/PDE3B has minimal impact on cyt‐cAMP.
Johannes Krier, David Spähn, David Arturo Juarez Lopez, Judith L. Nono, Judith Seigner, Lisa Jacob, Siegfried Ussar, Robert Lukowski, Andreas L. Birkenfeld, Gencer Sancar   +9 more
wiley   +1 more source

β-Adrenergic Receptor Desensitization/Down-Regulation in Heart Failure: A Friend or Foe? [PDF]

Front Cardiovasc Med, 2022
Mahmood A, Ahmed K, Zhang Y.
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Functional and phosphoproteomic analysis of β-adrenergic receptor signaling at excitatory synapses in the CA1 region of the ventral hippocampus. [PDF]

Sci Rep, 2023
Jami SA, Wilkinson BJ, Guglietta R, Hartel N, Babiec WE, Graham NA, Coba MP, O'Dell TJ.   +7 more
europepmc   +1 more source

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade, Nathan Morris, Diana E. Sepulveda, Alonso Cortez‐Resendiz, Christopher Brandl, Jennifer E. Lausch, Mariya Starostina, Nicholas M. Graziane   +7 more
wiley   +1 more source

The function of Foxp1 represses β-adrenergic receptor transcription in the occurrence and development of bladder cancer through STAT3 activity. [PDF]

Open Med (Wars), 2023
Ding Z, Jiao B, Chen X, Chen X, Jiao Y, Wang J, Zhou X.   +6 more
europepmc   +1 more source